Given that RRAD knockdown sensitizes chemo-resistant cancer cells to cytotoxic drugs, targeting STAT3 with oxeladin or butamirate may attenuate temozolomide resistance and glioblastoma recurrence after treatment [38,60]. Here, RRAD is linked to cancer.